Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00945646 · ClinicalTrials.gov registry record · Phase 3
FST-201 In The Treatment of Acute Fungal Otitis Externa
A Phase 3 study, sponsored by Shire.
- Terminated
- Registry status
- Phase 3
- Development phase
- 6
- Enrollment target
NCT00945646: Clinical Trial Phase 3 study, sponsored by Shire.
NCT00945646 is a Phase 3 study that was terminated before completion, run by Shire. The registered enrollment target is 6 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00945646, a Phase 3 study, was terminated before completion, sponsored by Shire.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 6 participants
- Enrollment target
Study Summary
The objective of this study is to evaluate the efficacy of FST-201 compared to vehicle in the treatment of acute fungal otitis externa. This trial is designed to enable filing of a New Drug Application in support of FST-201 for the indication of acute fungal otitis externa.
Interventions
- DRUG Vehicle
- DRUG FST-201 (dexamethasone 0.1%) Otic Suspension
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2009-07-31 |
| Est. Completion | 2010-07-31 |
| Phase | Phase 3 |
Why NCT00945646 stopped before completion
NCT00945646 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 6 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 2 interventions - of which Vehicle is the first listed.
NCT00945646 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00945646 about?
NCT00945646 is a clinical study titled "FST-201 In The Treatment of Acute Fungal Otitis Externa". The objective of this study is to evaluate the efficacy of FST-201 compared to vehicle in the treatment of acute fungal otitis externa. This trial is designed to enable filing of a New Drug Application in support of FST-201 for the indication of acute fungal otitis externa.
What is the current status of trial NCT00945646?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 6 participants. The study started on 2009-07-31. Estimated completion is 2010-07-31.
What interventions are being tested in trial NCT00945646?
The interventions under investigation include: Vehicle (DRUG), FST-201 (dexamethasone 0.1%) Otic Suspension (DRUG).
Who is sponsoring clinical trial NCT00945646?
This trial is sponsored by Shire, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00945646's enrollment target sits among peer trials
6 1995th of 2000 higher than 4 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI